ライフサイエンスコーパス: imidodiphosphate

1 e ATP analogue ADPNP (5'-adenylyl beta,gamma-imidodiphosphate).

2 (addition of MgCl2 + 5'-adenylyl-beta,gamma-imidodiphosphate).

3 2) determined with or without bound adenylyl imidodiphosphate.

4 trate analogs beryllium fluoride or adenylyl-imidodiphosphate.

5 oils with a nonhydrolyzable analog, adenylyl imidodiphosphate.

6 yzable analog of ATP, 5'-adenylyl-beta,gamma-imidodiphosphate.

7 denosine 5'-O-(3-thiotriphosphate) or adenyl-imidodiphosphate.

8 5'-triphosphate (GTP) analogue, 5'-guanylyl-imidodiphosphate.

9 vitro by ATP and the ATP analog adenyl-5'-yl imidodiphosphate.

10 PPases in a ternary complex with Mg(2+) and imidodiphosphate.

11 the nonhydrolyzable ATP analogue 5'-adenylyl imidodiphosphate.

12 ed in the presence of 5'-adenylyl beta,gamma-imidodiphosphate.

13 ed conformation upon the binding of adenylyl-imidodiphosphate.

14 ce of nonhydrolyzable 5'-adenylyl-beta,gamma-imidodiphosphate, a third state, which is identical with

15 eotide analogs, ADP, 5'-adenylyl-beta, gamma-imidodiphosphate, adenosine 5'-(beta,gammaimino)triphosp

16 lyzable ATP analogue 5'-adenylyl-beta, gamma-imidodiphosphate (ADPNP) to Escherichia coli DNA gyrase

17 lysable ATP analogue, 5'-adenylyl beta,gamma-imidodiphosphate (ADPNP).

18 ex with an ATP analogue, adenylyl-beta-gamma-imidodiphosphate (ADPNP).

19 rolysable ATP analog, 5'-adenylyl-beta,gamma-imidodiphosphate (ADPNP).

20 ration of the ATP binding site with adenylyl imidodiphosphate afforded protection against photolabeli

21 ex in the presence of 5'-adenylyl-beta,gamma-imidodiphosphate, albeit with a lower efficiency than th

22 ) and in complex with verapamil and adenylyl imidodiphosphate (AMP-PNP) (3.2 angstrom).

23 able analogs of ATP, 5'-adenylyl beta, gamma-imidodiphosphate (AMP-PNP) and adenosine 5'-(alpha, beta

24 monstrate here that nonhydrolyzable adenylyl-imidodiphosphate (AMP-PNP) can be used to preload CMG on

25 The inhibitor adenylyl imidodiphosphate (AMP-PNP) induces stochastic pauses in

26 P and the non-hydrolysable analogue adenylyl imidodiphosphate (AMP-PNP) partially substituted for ATP

27 since the nonhydrolyzable analogue adenylyl imidodiphosphate (AMP-PNP) protects equally well.

28 drolyzable ATP analog 5'-adenylyl-beta,gamma-imidodiphosphate (AMP-PNP) similarly stabilize the packa

29 logues of ATP, ADP, and 5'-adenyl-beta,gamma-imidodiphosphate (AMP-PNP) with the two domains of funct

30 TP is two times more effective than adenylyl imidodiphosphate (AMP-PNP), a hydrolysis-resistant ATP a

31 ) as did replacing pipette ATP with adenylyl imidodiphosphate (AMP-PNP), a non-hydrolysable analogue.

32 Delay of closing in wild type by adenylyl imidodiphosphate (AMP-PNP), a non-hydrolysable ATP analo

33 In adenylyl-imidodiphosphate (AMP-PNP), a nonhydrolyzable ATP analog

34 nhydrolyzable analog 5'-adenylyl-beta, gamma-imidodiphosphate (AMP-PNP), ADP, or ADP + Pi using both

35 mogenates with ATP or its analogue, adenylyl imidodiphosphate (AMP-PNP), is required for the strong a

36 ADPs was replaced with adenylyl beta, gamma-imidodiphosphate (AMP-PNP), some protection from cold di

37 ATP analog, adenosine 5'-adenylyl-beta,gamma-imidodiphosphate (AMP-PNP), was determined at 2.6 A reso

38 lyzable ATP analogue, 5'-adenylyl beta,gamma-imidodiphosphate (AMP-PNP), was investigated by using th

39 cellular ATP, as well as GTP and 5'-adenylyl-imidodiphosphate (AMP-PNP), were accompanied by a corres

40 lyzable ATP analogue, 5'-adenylyl-beta,gamma-imidodiphosphate (AMP-PNP), which in the gating models w

41 us-end vesicle motor followed by 5'-adenylyl imidodiphosphate (AMP-PNP)-induced microtubule affinity

42 by the weak agonist, 5'-adenylyl-beta,gamma-imidodiphosphate (AMP-PNP).

43 -(thiotriphosphate) (ATPgammaS) and adenylyl-imidodiphosphate (AMP-PNP).

44 erivatives of ADP and 5'-adenylyl-beta,gamma-imidodiphosphate (AMPPNP) also indicate an interaction s

45 Preincubation of vesicles with AMP imidodiphosphate (AMPPNP), a hydrolysis-resistant ATP an

46 The presence of 5'-adenylyl-beta,gamma-imidodiphosphate (AMPPNP), a nonhydrolyzable ATP analog,

47 hate (AMP), and of an ATP analogue, adenylyl imidodiphosphate (AMPPNP), bound to Escherichia coliaden

48 drolyzable ATP analog 5'-adenylyl-beta,gamma-imidodiphosphate (AMPPNP).

49 ation of enzyme-bound AdoMet and 5'-adenylyl imidodiphosphate (AMPPNP).

50 y relevant complexes, 5'-adenylyl-beta,gamma-imidodiphosphate (AMPPNP).Mg(2+), AMPPNP.Mg(2+).pantothe

51 f the nonhydrolyzable ATP analogues adenylyl-imidodiphosphate and adenosine 5'-O-thiotriphosphate.

52 nhibited by KF, by the pyrophosphate analogs imidodiphosphate and aminomethylenediphosphonate (AMDP),

53 hate analogs aminomethylenediphosphonate and imidodiphosphate and by KF and N-ethylmaleimide in a dos

54 are occupied by the GTP analogue 5'-guanylyl imidodiphosphate and the next three by GDP, which is sug

55 M of the kinesin inhibitor AMP-PNP (adenylyl-imidodiphosphate) and by anti-kinesin antibody but only

56 strong binding of S-1.MgAMP-PNP (5'-adenylyl imidodiphosphate) and on the weak binding of S-1.MgADP.P

57 iphosphate)), AMPPNP (5'-adenylyl beta,gamma-imidodiphosphate), and ADP, but not AMP.

58 by isoproterenol, sodium fluoride, guanyl-5'-imidodiphosphate, and forskolin in hypoxic membranes was

59 erationally simple single-flask synthesis of imidodiphosphate-based Bronsted acids.

60 While ATP or AMP-PNP (adenylyl-imidodiphosphate) binding to wild-type myosin subfragmen

61 onfirmed by the presence of four 5'-adenylyl-imidodiphosphate-binding sites (K(D) = 4.1 x 10(-6)m) pe

62 well to the binding affinity to the guanylyl imidodiphosphate-bound Cdc42, suggesting a rapid equilib

63 well to the binding affinity to the guanylyl imidodiphosphate-bound Rac1, which ranges from 10.5 to 4

64 insensitive to ATP or 5'-adenylyl-beta,gamma-imidodiphosphate but was blocked by ADP-AlF3 or ADP-vana

65 C]Phe-tRNA-elongation factor Tu.guanyl-5'-yl imidodiphosphate) but not [14C]Phe-tRNA.elongation facto

66 d by the nonhydrolyzable GTP analog guanylyl imidodiphosphate by a Ran mutant that is unable to hydro

67 ate analogs, amynomethylenediphosphonate and imidodiphosphate, by dicyclohexylcarbodiimide, and by th

68 Using a confined imidodiphosphate catalyst, the reaction delivers diverse

69 nase and its AMP-PNP (5'-adenylyl-beta,gamma-imidodiphosphate) complex to 2.1-angstroms resolutions.

70 e locked in an ADP or 5'-adenylyl-beta,gamma-imidodiphosphate conformation by the cross-linking with

71 lysis of the intact SGS revealed an adenylyl imidodiphosphate-dependent change in protection in the r

72 -(3-thiotriphosphate) (ATPgammaS) and adenyl-imidodiphosphate, each stabilized the primer recognition

73 drolyzable ATP analog 5'-adenylyl-beta,gamma-imidodiphosphate exhibits altered DNA gate dynamics, but

74 ls was found to be activated by guanyl-5'-yl imidodiphosphate (GMPPNP) and was identified as an effec

75 Gialpha1 were: mGTPgammaS > MANT-5'-guanylyl-imidodiphosphate > MANT-guanylyl-(beta,gamma-methylene)-

76 n II ATP-Mg(2+) = ATP = AMP-PNP (5'-adenylyl imidodiphosphate) > pyrophosphate = tripolyphosphate > t

77 osphazonium salts, providing rapid access to imidodiphosphates (IDP), iminoimidodiphosphates (iIDP),

78 e to form 1,3-dioxanes, using confined imino-imidodiphosphate (iIDP) Bronsted acid catalysts.

79 A new class of highly acidic confined imino-imidodiphosphate (iIDP) Bronsted acids catalyze the asym

80 d even in the presence of Ca(2+) or adenylyl-imidodiphosphate, indicating that the mechanism of stimu

81 The presence of the substrate analog, imidodiphosphate mediated two sites at the pathway entra

82 hydrolysable analogue 5'-adenylyl beta,gamma-imidodiphosphate, microcin B17 stabilises a gyrase-depen

83 Potassium fluoride, imidodiphosphate, N,N'-dicyclohexylcarbodiimide, and N-e

84 complex with nucleotides, ADP, and adenylyl-imidodiphosphate (non-hydrolysable analog of ATP).

85 imido analogue of the product pyrophosphate, imidodiphosphate (O(3)P-NH-PO(3)(4)(-)) also displays sl

86 g(2+) coordinated to 5'-adenylyl beta, gamma-imidodiphosphate or ADP bound to catalytic sites of beta

87 ions locked by either 5'-adenylyl beta,gamma-imidodiphosphate or the anticancer drug ICRF-193.

88 x with the ATP analog 5'-adenylyl beta,gamma-imidodiphosphate or the nucleoside sangivamycin crystall

89 ng the nonhydrolyzable ATP analog 5-adenylyl-imidodiphosphate or UTP for ATP in the pipette.

90 '-adenylyl methylenediphosphate, 5'-adenylyl imidodiphosphate, or 5'-adenylyl-O-(3-thiotriphos-phate)

91 ging CFTR activity with vanadate or adenylyl-imidodiphosphate, or by introducing the Walker A mutatio

92 tion in response to isoproterenol, guanyl-5'-imidodiphosphate, or forskolin.

93 Subsequent introduction of adenylyl imidodiphosphate precipitated a burst of large-amplitude

94 e presence of AMPPNP (5'-adenylyl-beta,gamma-imidodiphosphate), providing a direct linkage between st

95 structures; it is closed in the 5'-adenylyl-imidodiphosphate state, but open in the ADP state.

96 he presence of pyrophosphate, phosphate, and imidodiphosphate, the numbers of interaction curves were

97 -substrate ATP analog 5'-adenylyl-beta,gamma-imidodiphosphate verified that ATP hydrolysis was requir

98 the ATP phosphorylation antagonist adenylyl-imidodiphosphate, with an ED50 of approximately 0.1 nM.